Abstract
In this issue of The Lancet, Helen Colhoun and colleagues report the results of the Collaborative Atorvastatin Diabetes Study (CARDS), and document the efficacy and safety of low-dose atorvastatin treatment in primary prevention of coronary heart disease in patients with type 2 diabetes at high-risk of coronary heart disease. Since our first report of the efficacy of statin therapy in lowering lipid concentrations in patients with type 2 diabetes,1 clinical trial evidence has accumulated in support of statins as the primary lipid-lowering drugs for these patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
